西妥昔单抗在中晚期食管癌化疗中的辅助作用研究

摘要

目的 探讨西妥昔单抗在中晚期食管癌化疗中的辅助作用.方法 将80例中晚期食管癌患者随机分为对照组和观察组,每组各40例.两组均给予顺铂联合5-氟尿嘧啶化疗方案治疗,观察组在此基础上加用西妥昔单抗治疗.比较两组治疗前后血清癌胚抗原(CEA)及鳞状细胞癌抗原(SCC)水平、临床疗效、毒副反应发生率及1年生存情况.结果 治疗后两组CEA及SCC均低于治疗前,且观察组低于对照组(均P<0.05);相较于对照组,观察组治疗有效率和疾病控制率高,毒副反应发生率低,3个月、6个月及1年生存率高(均P<0.05).结论 西妥昔单抗辅助治疗中晚期食管癌,能显著降低血清CEA及SCC水平,提高临床治疗效果,减少治疗毒副作用,延长患者生存时间.%Objective To investigate the auxiliary effect of cetuximab in the chemotherapy for intermediate and advanced esophageal cancer.Methods A total of 80 patients with intermediate and advanced esophageal cancer were randomly divided into control group and observation group,with 40 cases in each group.The two groups were all treated with chemotherapy regimen of cisplatin combined with 5-fluorouracil,on the basis of this regime,the observation group was given cetuximab additionally.The levels of serum carcinoembryonic antigen(CEA) and squamous cell carcinoma antigen(SCC) before and after treatment,clinical efficacy,incidence rate of toxic and adverse reactions,and 1-year survival rate were compared between the two groups.Results After treatment,the levels of CEA and SCC decreased in the two groups,and the levels in the observation group were lower than those in the control group(all P<0.05).Compared to the control group,the observation group had higher therapeutic effective rate and disease control rate,lower incidence rate of toxic and adverse reactions,and higher 3-,6-month and 1-year survival rates(all P<0.05).Conclusion Cetuximab can significantly reduce serum levels of CEA and SCC,improve clinical therapeutic effects,reduce therapeutic side effects,and prolong survival time in the treatment of intermediate and advanced esophageal cancer.